Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...

Aberrant B-cell function, which could arise from various underlying causes, is central to the pathogenesis of diverse ...

Blocking of IL-7R inhibited the upregulation of RAG expression by autoreactive B220 low B cells, thereby preventing receptor revision following antigen recognition. The ability to prevent the ...

EsoBiotec develops therapies that engineer immune cells within the body, eliminating the need for patients to go through lymphodepletion and reinfusion.